Netherlands · Delayed Price · Currency is EUR Lakefront Biotherapeutics NV Earnings Call Transcripts
Fiscal Year 2026
-
The company has undergone a major transformation, focusing on T-cell engagers and securing gamgertamig as a lead asset with Gilead as a key partner. Registration studies in autoimmune diseases are set for next year, supported by strong financials and a robust pipeline. Regulatory and industry trends are favorable.
-
Q1 2026 saw a major transformation, including a new name, leadership, and a pivotal partnership with Gilead for Ouro Medicines' portfolio. Financials improved with a net profit of EUR 14.5 million and robust cash reserves, while guidance reflects significant investment in new programs and continued capital discipline.
Fiscal Year 2025
-
A major restructuring will split the business into a cell therapy-focused entity and SpinCo, which will pursue acquisitions in oncology, immunology, and virology with €2.45 billion in capital. The cell therapy platform features rapid, decentralized manufacturing and strong clinical data, while both entities are positioned for long-term value creation.